BACKGROUND: Ovarian cancer constitutes one of the most lethal gynecologic malignancies for females. Currently, early detection strategies and therapeutic options for ovarian cancer are far from satisfactory, leading to high diagnosis rates at late stages and disease relapses. New avenues of therapy are needed that target key processes in ovarian cancer progression. While a variety of non-coding RNAs have been proven to regulate ovarian cancer metastatic progression, the functional roles of RNA-binding proteins (RBPs) in this process are less well defined.
RESULTS: In this study, we identify that the RBP sorbin and SH3 domain containing 2 (SORBS2) is a potent suppressor of ovarian cancer metastatic colonization. Mechanistic studies show that SORBS2 binds the 3' untranslated regions (UTRs) of WFDC1 (WAP four-disulfide core domain 1) and IL-17D (Interleukin-17D), two secreted molecules that are shown to act as metastasis suppressors. Enhanced expression of either WFDC1 or IL-17D potently represses SORBS2 depletion-mediated cancer metastasis promotion. By enhancing the stability of these gene transcripts, SORBS2 suppresses ovarian cancer invasiveness and affects monocyte to myeloid-derived suppressor cell and M2-like macrophage polarization, eliciting a tumor-suppressive immune microenvironment.
CONCLUSIONS: Our data illustrate a novel post-transcriptional network that links cancer progression and immunomodulation within the tumor microenvironment through SORBS2-mediated transcript stabilization.
Recommended CitationZhao, Linjie; Wang, Wei; Huang, Shuang; Yang, Zhengnan; Xu, Lian; Yang, Qilian; Zhou, Xiu; Wang, Jinjin; Shen, Qiuhong; Wang, Chenlu; Le, Xiaobing; Feng, Min; Zhou, Nianxin; Lau, Wayne Bond; Lau, Bonnie; Yao, Shaohua; Yi, Tao; Wang, Xin; Zhao, Xia; Wei, Yuquan; and Zhou, Shengtao, "The RNA binding protein SORBS2 suppresses metastatic colonization of ovarian cancer by stabilizing tumor-suppressive immunomodulatory transcripts." (2018). Department of Emergency Medicine Faculty Papers. Paper 72.
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.